Key Takeaways
· Partnership formed: Atelerix and Cherry Biotech team up to merge hydrogel and organoid tech.
· Trial period: 12‑month pilot to align strategy and build long‑term collaboration.
· Global impact: Enables stable shipment of organoids, expanding access to reliable preclinical data.
Alterix, a biotech company specialising in cell preservation and biological transport with its unique hydrogel encapsulation technology, announced today that it has signed an agreement with Cherry Biotech, a company with expertise in organ-on-chip and organoid technologies.
In the short term, this partnership will examine the integration of Aterlerix’s patented hydrogel technology with Cherry Biotech’s state-of-the-art 3D organoid models to foster global extended-duration shipment. Together, the companies aim to improve the reliability and consistency of transporting these temperature-sensitive materials without added complications associated with cold-chain logistics. This enables significant growth and expanded customer access to high-quality, human-relevant preclinical data worldwide.
The agreement outlines that there will be an initial 12-month trial period, allowing both parties to put their strategic and technical alignment into place and establish the groundwork for a scalable, long-term commercial partnership.
Cherry Biotech’s in vitro products combine AI analysis, high-resolution live imaging, and precisely controlled organoid culture to enhance efficacy predictions and safety assessments of drugs, generating real-life-like preclinical data.
As part of the partnership, Atelerix’s hydrogel technology will also be validated for the stable shipment of Cherry Biotech’s recently released organoidPlate – an advanced multiwell plate with ready-to-use organoids for adipose tissue, breast cancer, liver, and lung, which is now available for worldwide shipping.
Alastair Carrington, CEO, Atelerix, commented: “This latest partnership with Cherry Biotech is a key step in expanding our commercial traction, broadening market reach, and increasing visibility for Atelerix’s solutions.” Overall, this partnership marks an opportunity to reinforce the potential of logistics to support the adoption of assay-ready animal model alternatives, advancing drug testing and better predicting human responses.
